Episodebeskrivelse
In this episode of The Connect Current, we sit down with James Mackay, Ph.D., President and CEO of Crystalys Therapeutics, to explore how the company is advancing a new treatment path for people living with gout. James shares how Crystalys is developing dotinurad, a next-generation, once-daily oral URAT1 inhibitor, and what the company’s recent $130 million Series B financing enables as it moves through late-stage global clinical development and commercialization preparation. The conversation dives into why gout remains an underserved treatment area, what it takes to execute at this stage of…
Website: theconnectcurrent.org

